The countdown to the domestic entry of an insulin decreasing the risk of hypoglycemia, pre-noticing a war of nerves

As the countdown has begun to the domestic launch of the next-generation basal insulin diabetes treatment having low risk of hypoglycemia, the markets concerned has shown high interests.

Recently, the Novo Nordisk’s next-generation basal insulin ‘Tresiba FlexTouch Inj.(generic name: insulin degludec, hereinafter referring to Tresiba)’ 100 units/ml and 200 units/ml were registered in the insura...